Editorial: 5‐ASA in IBD patients on biologics—‘stop or continue’?

Veyrard, Pauline; Nancey, Stéphane; Roblin, Xavier

doi:10.1111/apt.16541

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, patients are traditionally treated with 5-aminosalicylic acid (5-ASA), corticosteroid and immunosuppressive medications. 6,7 In addition, antibody therapeutics that directly inhibit immune cytokines or receptors are widely used. This class of drugs has the advantage of being relatively safe compared to traditional drugs, but has the disadvantage that it is ineffective in some patients and may develop resistance.…”

Section: Introductionmentioning

confidence: 99%

Bovine colostrum derived-exosomes prevent dextran sulfate sodium-induced intestinal colitis via suppression of inflammation and oxidative stress

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Bovine colostrum derived-exosomes prevent dextran sulfate sodium-induced intestinal colitis via suppression of inflammation and oxidative stress

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Guidelines recommend aminosalicylic acid preparations as first-line agents to induce and maintain remission in mild-to-moderate UC. 5-ASA is the mainstay of treatment for mild ulcerative, with approximately 50% of patients achieving sustained clinical remission 107. For CD, evidence suggests that aminosalicylic acid preparations are ineffective and are not recommended by most clinical guidelines108,109 ; however, they are still widely used to induce and maintain remission in patients with mild CD whose lesions areF I G U R E 2 Medical treatment flowchart of inflammatory bowel disease (IBD).…”

mentioning

confidence: 99%

Diagnosis and management of inflammatory bowel disease

Li,

Cheng,

et al. 2024

J Evidence Based Medicine

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic and relapsing immune‐mediated disease of the gastrointestinal tract with a gradually increasing global incidence and prevalence. A prolonged course of IBD leads to a decline in patient quality of life and the creation of a substantial economic burden on society. Owing to the lack of specific diagnostic markers, the diagnosis of IBD still needs a gold standard based on a combination of clinical manifestations, imaging, laboratory, and endoscopic results. Accordingly, the current goals of IBD treatment are to alleviate clinical symptoms and reduce recurrence rates. Therefore, it is imperative to develop a standard set of procedures to diagnose and treat IBD. In this review, we summarize prominent and emerging studies, outline classical and contemporary approaches to diagnosing and managing IBD, and integrate multiple guidelines. Furthermore, we propose the possibility of establishing an early and comprehensive diagnostic workflow and personalized management strategy in the future. We aim to enhance the quality and standardization of diagnostic and treatment procedures for IBD.

show abstract